Pharmacological Reports 66 (2014) 699–703

Contents lists available at ScienceDirect

Pharmacological Reports

journal homepage: www.elsevier.com/locate/pharep

Short communication

Involvement of leukotriene B_4 in dermatophyte-related itch in mice

Tsugunobu Andoh, Yusuke Takayama, Yasushi Kuraishi *

Department of Applied Pharmacology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Sugitani, Japan

ARTICLE INFO

Article history:
Received 20 June 2013
Received in revised form 27 December 2013
Accepted 3 January 2014
Available online 26 April 2014

Keywords:
Dermatophyte
Itch
Leukotriene B_4
5-Lipoxygenase
Proteinase-activated receptor 2

ABSTRACT

Background: Proteinase-activated receptor-2 (PAR_2) is involved in dermatophyte-induced scratching and leukotriene B_4 (LTB_4) release from keratinocytes. We investigated whether PAR_2-mediated LTB_4 production is involved in dermatophyte-induced scratching.
Methods: Dermatophyte extract was injected intradermally and scratching was observed in mice. LTB_4 was determined by enzyme immunoassay.
Results: Dermatophyte extract-induced scratching was inhibited by zileuton (5-lipoxygenase inhibitor), ONO-4057 (LTB_4 antagonist), FSLLRY-NH_2 (PAR_2 antagonist), and anti-PAR_2 antibody. Dermatophyte extract injection increased the cutaneous content of LTB_4, which was inhibited by zileuton and FSLLRY-NH_2.
Conclusion: These results suggest the involvement of LTB_4 in dermatophyte-associated itch. LTB_4 production might be due to PAR_2 stimulation in the skin.

Introduction

Dermatophytosis (or tinea) is caused by a fungal infection, typically by dermatophytes. The most common functional symptom of tinea pedis is pruritus, which is reported by about 60% of patients with moderate or severe tinea pedis [9]. Details of the underlying mechanisms of dermatophytosis-associated pruritus remain poorly understood. During the infection process, dermatophytes secrete various enzymes, including proteases [15]. Of these secreted enzymes, proteases, and especially endopeptidases (proteinases), cause itching in humans and itch-related behavior in mice when administered to the skin [8,18]. Proteinase-activated receptor 2 (PAR_2) has been implicated as having an important role in proteinase-mediated itching [18].

Trichophyton mentagrophytes, including *Arthroderma vanbreuseghemii* (ADV), is known to infect both animals and humans [10]. Intradermal injection of ADV extract into the rostral back of mice elicits an itch-related response (hind-paw scratching), which has been shown to be suppressed by both a serine protease inhibitor and a PAR_2 antagonist [7]. Taken together, these findings suggest the possibility that proteinases secreted by dermatophytes cause itching through the stimulation of PAR_2 receptors in the skin.

An injection of SLIGKV-NH_2 (tethered ligand peptide of human PAR_2 receptor) into the human skin provokes itch and pain [17]. Injections of pruritogenic and algogenic substances (such as histamine and capsaicin, respectively) into the murine cheek elicit hind-paw scratching and pain-related behavior (forelimb wiping) of the injection site, respectively [16], and an injection of SLIGRL-NH_2 (tethered ligand peptide of murine PAR_2 receptor) into the murine cheek provokes marked hind-paw scratching and little forelimb wiping, suggesting that stimulation of PAR_2 receptor in the skin mainly induces itching in mice [1]. Similarly, an injection of ADV extract into the murine cheek increased markedly hind-paw scratching and only slightly forelimb wiping, suggesting that ADV extract is pruritogenic with weak algogenic activity [7]. ADV extract-induced scratching is inhibited by a PAR_2 antagonist, which suggests that ADV extract-induced scratching is mediated by PAR_2 receptors in the skin [7].

PAR_2 receptors are expressed in epidermal keratinocytes [17] and nerve fibers in the skin [17]. Because dermatophytes infect the superficial skin and require keratin for growth [12], the epidermis may be a key site of pruritic dermatophyte infection. Epidermal keratinocytes produce itch mediators [5,6]. Of these, leukotriene (LT) B_4, a potent itch mediator [2], is produced by keratinocytes in response to pruritogenic stimuli [5,6] and is involved in dermatitis-associated pruritus [4]. The activation of PAR_2 receptors on keratinocytes has been shown to induce LTB_4 production [20]. Therefore, the purpose of this study was to determine whether

* Corresponding author.
E-mail address: kuraisiy@pha.u-toyama.ac.jp (Y. Kuraishi).

http://dx.doi.org/10.1016/j.pharep.2014.01.003
1734-1140/

LTB_4 produced by epidermal keratinocytes is involved in itching induced by ADV extract.

Materials and methods

Animals

Male Slc:ICR mice (5–8 weeks old) were purchased from Japan SLC (Hamamatsu, Japan). They were housed in a room under controlled temperature (21–23 °C), humidity (45–65%), and light (7:00 AM to 7:00 PM) conditions. Food and water were available ad libitum. The study protocol was approved by the Committee for Animal Experiments at the University of Toyama.

Materials

Zileuton (Sigma, St. Louis, MO, USA), indomethacin (Sigma), and 5-[2-(2-carboxyethyl)-3-[6-(4-methoxyphenyl)-5E-hexenyl] oxyphenoxy] valeric acid (ONO-4057; Ono Pharmaceutical Co., Ltd., Osaka, Japan) were dissolved in 0.5% carboxymethyl cellulose (Wako Pure Chemical Ind., Osaka, Japan). Diclofenac sodium (Research Biochemical Inc., Natick, MA, USA) was dissolved in tap water. Zileuton and ONO-4057 were administered orally 1 h before ADV extract injection, and indomethacin and diclofenac were administered orally 30 min before ADV extract injection. FSLLRY-NH_2 (selective PAR_2 antagonist peptide) was dissolved in saline and was injected intradermally together with ADV extract. Anti-PAR_2 monoclonal antibody (SAM-11, which has epitope of amino acid 37–50 of human PAR_2 containing the tethered ligand sequence and binds to human and murine PAR_2, according to the manufacturer's specifications; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and non-specific mouse IgG were dissolved in phosphate-buffered saline and injected intradermally 10 min before ADV extract injection. The doses of zileuton, ONO-4057, indomethacin, diclofenac, FSLLRY-NH_2, and antibody SAM-11 were selected from the published literature [5,6,18].

Dermatophytes and extract preparation

The dermatophyte ADV (ID #58445) was obtained from the National BioResource Project (http://www.nbrp.jp/). It was cultured in Sabouraud's dextrose liquid culture medium at 37 °C for more than 3 days. ADV extract was prepared as described previously [7].

Behavior experiments

The day before behavior experiments, the animals' hair was clipped over the rostral part of the back. For acclimation, mice were placed individually in an acrylic cage composed of four cells (13 cm × 9 cm × 35 cm) for at least 1 h prior to testing. Immediately after intradermal injection, mice were returned to the same cells, and their behaviors were videotaped for 1 h. No personnel were present in the observation room during this time. Playback of the video allowed for counting of injection site scratching by the hind paw. The series of movements in which the mice stretched either hind paw toward the injection site, leaned the head toward it, and rapidly scratched several times for about 1 s were considered as one bout of scratching [7].

LTB_4 enzyme immunoassay

The skin (8 mm in diameter) at the injection site was removed 5 min after injection, immediately weighed, shredded using scissors, and put into 0.2 mL of ice-cold ethanol containing 10 μM indomethacin and 10 μM zileuton. Lipid extraction and LTB_4 enzyme immunoassay were performed as previously described [4].

Data processing

Data are presented as means ± standard error of the mean (SEM). Data were analyzed with a Student's *t*-test, two-way repeated measures analysis of variance (ANOVA) and *post hoc* Tukey's test, or one-way ANOVA and *post hoc* Dunnett's test or Holm–Šidák test; $p < 0.05$ was considered significant. The statistical analyses were performed using Sigmaplot graphing and statistical software (version 11; Systat Software, Inc., Chicago, IL, USA).

Results

Scratching behavior induced by ADV extract

An intradermal injection of ADV extract (20 μg/site) into the rostral back elicited hind-paw scratching toward the injection site, inducing no other apparent behavioral responses. This effect peaked during the first 10-min period and almost completely subsided after 30 min (Fig. 1A). When scratching during the 1-h duration was compared between treatment groups, we found that ADV extract increased scratching bouts 2.2-fold compared to control (Fig. 1B).

Effects of inhibitors of 5-lipoxygenase, cyclooxygenase, and the LTB_4 receptor on ADV extract-induced scratching

Scratching induced by ADV extract (20 μg/site) was markedly inhibited by oral pretreatment with the 5-lipoxygenase inhibitor zileuton (10–100 mg/kg) and the LTB_4 receptor antagonist ONO-4057 (10–100 mg/kg). Nearly complete inhibition was observed after treatment with 30 and 100 mg/kg of zileuton or treatment



Fig. 1. Scratching response to an intradermal injection of dermatophyte extract into the rostral back in mice. Hind-paw scratching of the injection site was counted for 60 min after an intradermal injection of an extract of the dermatophyte *Arthroderma vanbreuseghemii* (ADV) or vehicle (VH). (A) Time-course of scratching after VH and ADV extract (20 μg/site) injections. *$p < 0.05$ vs. VH (Tukey's test). (B) Total number of scratching bouts for 1 h. *$p < 0.05$ (Student's *t*-test). The values represent the mean ± SEM ($n = 16$).



Fig. 2. Effects of inhibition of eicosanoid systems on dermatophyte extract-induced scratching in mice. Hind-paw scratching of the injection site was counted for 60 min after an intradermal injection of *Arthroderma vanbreuseghemii* (ADV) extract (20 μg/site). (A) Zileuton or vehicle (VH1, 0.5% carboxymethyl cellulose) was administered orally 60 min before ADV extract injection. $n = 8$ in each group. (B) ONO-4057 or VH1was administered orally 60 min before ADV extract injection. $n = 16$ each group. (C) Indomethacin or VH1 was administered orally 30 min before ADV extract injection. $n = 8$ in each group. (D) Diclofenac sodium or VH2 (tap water) was administered orally 30 min before ADV extract injection. $n = 8$ in each group. Dashed lines represent the average value of scratch bouts in mice given intradermal injection of saline. The values represent the mean ± SEM. $^*p < 0.05$ vs. VH1 or VH2 (Dunnett's test). These experiments were performed twice and similar results were obtained.

with 100 mg/kg of ONO-4057 (Fig. 2A and B). Oral pretreatment with the cyclooxygenase inhibitors indomethacin (1–10 mg/kg) or diclofenac sodium (1–10 mg/kg) had a tendency to decrease the ADV extract-induced scratching, but the effects were not statistically significant (Fig. 2C and D).



Fig. 3. Effects of PAR_2 antagonist and anti-PAR_2 antibody (Ab) on dermatophyte extract-induced scratching in mice. Hind-paw scratching of the injection site was counted for 60 min after an intradermal injection of *Arthroderma vanbreuseghemii* (ADV) extract (20 μg/site). (A) ADV extract was injected intradermally with or without the PAR_2 antagonist FSLLRY-NH_2 (30 and 100 μg/site). (B) Anti-PAR_2 monoclonal Ab (1 and 10 μg/site) and non-specific IgG (nIgG, 10 μg/site) were injected intradermally 10 min before ADV extract injection. The dashed line represents the average value of scratch bouts in mice given an intradermal injection of saline. The values represent the mean ± SEM ($n = 8$). $^*p < 0.05$ vs. nIgG (Dunnett's test). These experiments were performed twice and similar results were obtained.

Effects of PAR_2 antagonist and anti-PAR_2 antibody on ADV extract-induced scratching

Scratching induced by ADV extract (20 μg/site) was markedly inhibited by intradermal co-injection with FSLLRY-NH_2 (30 and 100 μg/site) (Fig. 3A). In addition, ADV extract-induced scratching was dose-dependently inhibited by intradermal pretreatment with a PAR_2 neutralizing antibody (1 and 10 μg/site) dose-dependently inhibited scratching induced by ADV extract (20 μg/site), as compared with a non-specific IgG (Fig. 3B).

LTB_4 production

Cutaneous LTB_4 content was significantly increased 5 min after intradermal injection of ADV extract (20 μg/site) (Fig. 4). This increase was significantly and almost completely prevented by oral pretreatment with zileuton (100 mg/kg) and intradermal co-injection with FSLLRY-NH_2 (100 μg/site) (Fig. 4).



Fig. 4. Increased production of leukotriene (LT) B_4 after dermatophyte extract injection in the mouse skin. *Arthroderma vanbreuseghemii* (ADV) extract (20 μg/site) and saline were injected intradermally, and 5 min later LTB_4 content was measured in the treated skin. Zileuton (ZLT, 100 mg/kg; $n = 9$) and the vehicle (VH; $n = 8$ in each group) were administered orally 1 h before ADV extract injection. FSLLRY-NH_2 (FSLLRY, 100 μg/site; $n = 8$) was injected intradermally together with ADV extract. The values represent the mean ± SEM. $^*p < 0.05$ vs. VH + saline, $^\#p < 0.05$ vs. VH + ADV extract (Holm–Šidák test). These experiments were performed twice and similar results were obtained.

Discussion

An intradermal injection of ADV extract (20 μg/site) elicited hind-paw scratching, confirming our previous report, which showed that intradermal ADV extract (1–20 μg/site) causes a dose-dependent increase in hind-paw scratching [7].

We have shown that ADV extract-induced scratching is inhibited by both the PAR_2 antagonist FSLLRY-NH_2 and the serine protease inhibitor nafamostat [7]. In the present study, we reconfirmed the inhibitory activity of FSLLRY-NH_2 and observed that a PAR_2-neutralizing antibody also inhibited ADV extract-induced scratching. The PAR_2 receptor is activated via the proteolytic cleavage of its N-terminal sequence by serine proteases. ADV extract cleaves a synthetic N-terminal peptide of PAR_2 similar to both trypsin and tryptase [7]. Therefore, serine protease(s) present in the ADV extract may elicit scratching through PAR_2 activation, although pruritogenic serine proteases have not yet been shown to be a component of ADV extract. In the skin, PAR_2 has been shown to be expressed mainly in nerve fibers [17] and epidermal keratinocytes [17]. Since ADV extract is equally effective at inducing scratching behavior in both mast cell-deficient mice and normal littermates [7], mast cells may not be essential for the pruritogenic action of ADV extract. Thus, an intradermal injection of ADV extract may primarily act on nerve fibers and epidermal keratinocytes to induce scratching.

ADV extract-induced scratching was inhibited by the LTB_4 receptor antagonist ONO-4057, suggesting that dermatophyte-associated itching involves LTB_4, a potent pruritogen in mice [2]. A key enzyme for LTB_4 production is 5-lipoxygenase [14]. Thus, the observation that the 5-lipoxygenase inhibitor zileuton suppressed scratching and LTB_4 production induced by the ADV extract supports the idea that LTB_4 is involved in dermatophyte-associated itching. Since ADV extract-induced scratching was fast in onset and short in duration, component and/or resident cells in the skin may be responsible. 5-Lipoxygenase is present in epidermal keratinocytes [4], and cultured keratinocytes produce LTB_4 upon stimulation with PAR_2 agonist [20]. Thus, it is plausible that PAR_2-mediated LTB_4 produced by epidermal keratinocytes is involved in ADV extract-induced scratching. Mast cells also produce LTB_4 following activation [13]. However, mast-cell deficiency does not reduce scratching induced by ADV extract or PAR_2 agonist [7], suggesting that mast cells do not play a key role in ADV extract-induced scratching. We do not rule out the possibility that LTB_4 produced by infiltrating leukocytes is involved under dermatitis conditions.

There are two LTB_4 receptor subtypes, BLT1 and BLT2, which have high and low binding affinities for LTB_4, respectively [19]. Since ONO-4057 has a similar affinity for BLT1 and BLT2 receptors [19], the results of the present study did not detect the relative contributions of BLT1 and BLT2 receptors in ADV extract-induced scratching. In the dorsal root ganglia and skin in normal mice, BLT1 receptor mRNA is expressed, but BLT2 receptor mRNA cannot be detected [3]. LTB_4 administration increases Ca^{2+} influx in cultured dorsal root ganglion neurons [3]. Most (73%) of the BLT1 immunoreactive neurons are small or medium in size and TRPV1 channel immunoreactivity (a marker of unmyelinated C-fiber neurons) has been shown to be present in BLT1-positive neurons [3]. Therefore, it is suggested that BLT1 receptors are responsible for an initiation phase of ADV extract-induced scratching. On the other hand, LTB_4 promotes the chemotaxis of leukocytes that express BLT1 and BLT2 receptors [19]. Therefore, it is possible that BLT2 receptors are involved in a late phase of ADV extract-induced scratching [11].

In this study, the cyclooxygenase inhibitors indomethacin and diclofenac did not significantly affect the ADV extract-induced scratching. Indomethacin does not inhibit scratching induced by PAR_2 agonist, substance P, and sphingosylphosphorylcholine in mice [5,6,20], although it inhibits prostaglandin E_2 production induced by PAR_2 agonist and substance P in cultured keratinocytes [5,20]. Intradermal injection of prostaglandin E_2 does not elicit scratching in mice [2]. With these findings taken into account, the present results suggest that although its production is increased by ADV extract, prostaglandin E_2 does not play a key role in ADV extract-induced scratching.

In summary, data shown here suggest that dermatophyte-contained serine protease(s) act on PAR_2 in the epidermis to produce LTB_4, which causes itching. This may be a causal mechanism of dermatophytosis-associated pruritus.

Conflict of interest

The authors state no conflict of interest.

Funding

This study was supported in part by a Grant-in-Aid for Young Scientists (B) from the Ministry of Education, Culture, Sports, Science, and Technology, Japan (19790051; 22790063), Grant-in-Aid for Scientific Research (B) from the Ministry of Education, Culture, Sports, Science and Technology, Japan (23390153), and Grants for Health Science from the Health, Labour and Welfare Ministry, Japan. This work was also supported in part by the National BioResource Project of Japan (http://www.nbrp.jp/).

Acknowledgement

We thank Dr. Jung-Bum Lee in the Department of Pharmacognosy, University of Toyama, for kindly providing FSLLRY-NH_2.

References

[1] Akiyama T, Carstens MI, Carstens E. Differential itch- and pain-related behavioral responses and μ-opioid modulation in mice. Acta Derm Venereol 2010;90:575–81.
[2] Andoh T, Kuraishi Y. Intradermal leukotriene B_4, but not prostaglandin E_2, induces itch-associated responses in mice. Eur J Pharmacol 1998;353:93–6.
[3] Andoh T, Kuraishi Y. Expression of BLT1 leukotriene B_4 receptor on the dorsal root ganglion neurons in mice. Mol Brain Res 2005;137:263–6.
[4] Andoh T, Haza S, Saito A, Kuraishi Y. Involvement of leukotriene B_4 in spontaneous itch-related behavior in NC mice with atopic dermatitis-like skin lesions. Exp Dermatol 2011;20:894–8.
[5] Andoh T, Katsube N, Maruyama M, Kuraishi Y. Involvement of leukotriene B_4 in substance P-induced itch-associated response in mice. J Invest Dermatol 2001;117:1621–6.
[6] Andoh T, Saito A, Kuraishi Y. Leukotriene B_4 mediates sphingosylphosphorylcholine-induced itch-associated responses in mouse skin. J Invest Dermatol 2009;129:2854–60.
[7] Andoh T, Takayama Y, Yamakoshi T, Lee JB, Sano A, Shimizu T, et al. Involvement of serine protease and proteinase-activated receptor 2 in dermatophyte-associated itch in mice. J Pharmacol Exp Ther 2012;343:91–6.
[8] Arthur RP, Shelley WB. Experimental evidence for an enzymatic basis for itching in man. Nature 1995;175:901–2.
[9] Cohen AD, Wolak A, Alkan M, Shalev R, Vardy DA. AFSS: athlete's foot severity score. A proposal and validation. Mycoses 2002;45:97–100.
[10] Drouot S, Mignon B, Fratti M, Roosje P, Monod M. Pets as the main source of two zoonotic species of the *Trichophyton mentagrophytes* complex in Switzerland. *Arthroderma vanbreuseghemii* and *Arthroderma benhamiae*. Vet Dermatol 2009;20:13–8.
[11] Fernandes ES, Vong CT, Quek S, Cheong J, Awal S, Gentry C, et al. Superoxide generation and leukocyte accumulation: key elements in the mediation of leukotriene B_4-induced itch by transient receptor potential ankyrin 1 and transient receptor potential vanilloid 1. FASEB J 2012;27:1664–73.
[12] Hainer BL. Dermatophyte infections. Am Fam Physician 2003;67:101–8.
[13] Lin TY, London CA. Characterization and modulation of canine mast cell derived eicosanoids. Vet Immunol Immunopathol 2010;135:118–27.
[14] Murphy RC, Gijón MA. Biosynthesis and metabolism of leukotrienes. Biochem J 2007;405:379–95.
[15] Peres NT, Maranhao FC, Rossi A, Martinez-Rossi NM. Dermatophytes: host-pathogen interaction and antifungal resistance. Ann Bras Dermatol 2010;85:657–67.

[16] Shimada SG, LaMotte RH. Behavioral differentiation between itch and pain in mouse. Pain 2008;139:681–7.
[17] Steinhoff M, Neisius U, Ikoma A, Fartasch M, Heyer G, Skov PS, et al. Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. J Neurosci 2003;23:6176–80.
[18] Ui H, Andoh T, Lee JB, Nojima H, Kuraishi Y. Potent pruritogenic action of tryptase mediated by PAR-2 receptor and its involvement in anti-pruritic effect of nafamostat mesilate in mice. Eur J Pharmacol 2006;530:172–8.
[19] Yokomizo T, Izumi T, Shimizu T. Leukotriene B_4: metabolism and signal transduction. Arch Biochem Biophys 2001;385:231–41.
[20] Zhu Y, Wang XR, Peng C, Xu JG, Liu YX, Wu L, et al. Induction of leukotriene B_4 and prostaglandin E_2 release from keratinocytes by protease-activated receptor-2-activating peptide in ICR mice. Int Immunopharmacol 2009;9:1332–6.

Journal of Dermatological Science 76 (2014) 206–213

Contents lists available at ScienceDirect

Journal of Dermatological Science

journal homepage: www.jdsjournal.com

Antipruritic mechanisms of topical E6005, a phosphodiesterase 4 inhibitor: Inhibition of responses to proteinase-activated receptor 2 stimulation mediated by increase in intracellular cyclic AMP

Tsugunobu Andoh, Yasushi Kuraishi *

Department of Applied Pharmacology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama 930-0194, Japan

ARTICLE INFO

Article history:
Received 16 July 2014
Received in revised form 11 September 2014
Accepted 14 October 2014

Keywords:
cAMP
Itch
Phosphodiesterase
Proteinase-activated receptor 2
Pruritus
Scratch

ABSTRACT

Background: Phosphodiesterase 4 (PDE4), which catalyses the conversion of cyclic adenosine 3′,5′-monophosphate (cAMP) to 5′-AMP, plays a critical role in the pathogenesis of inflammatory disorders. Pruritus is the main symptom of dermatitides, such as atopic dermatitis, and is very difficult to control. Recent studies have shown that the activation of proteinase-activated receptor 2 (PAR_2) is involved in pruritus in dermatoses in humans and rodents.

Objective: To investigate the inhibitory effect of E6005, a topically effective PDE4 inhibitor, on PAR_2-associated itching in mice.

Methods: Mice were given an intradermal injection of SLIGRL-NH_2 (100 nmol/site), a PAR_2 agonist peptide, into the rostral part of the back. E6005 and 8-bromo-cAMP were applied topically and injected intradermally, respectively, to the same site. Scratching bouts were observed as an itch-related behavior, and firing activity of the cutaneous nerve was electrophysiologically recorded. Keratinocytes were isolated from the skin of neonatal mice and cultured for in vitro experiments. The concentrations of cAMP and leukotriene B_4 (LTB_4) were measured by enzyme immunoassay. The distribution of PDE4 subtypes in the skin was investigated by immunostaining.

Results: Topical E6005 and intradermal 8-bromo-cAMP significantly inhibited SLIGRL-NH_2-induced scratching and cutaneous nerve firing. Topical E6005 increased cutaneous cAMP content. Topical E6005 and intradermal 8-bromo-cAMP inhibited cutaneous LTB_4 production induced by SLIGRL-NH_2, which has been shown to elicit LTB_4-mediated scratching. E6005 and 8-bromo-cAMP inhibited SLIGRL-NH_2-induced LTB_4 production in the cultured murine keratinocytes also. PDE4 subtypes were mainly expressed in keratinocytes and mast cells in the skin.

Conclusions: The results suggest that topical E6005 treatment inhibits PAR_2-associated itching. Inhibition of LTB_4 production mediated by an increase in cAMP may be partly involved in the antipruritic action of E6005.

1. Introduction

Itch (or pruritus) is a skin sensation that provokes a desire to scratch and is the most common symptom of dermatitides (e.g., atopic dermatitis) and some systemic disorders (e.g., cholestasis). Although the use of antihistamines and short-term use of topical glucocorticosteroids are supplemented by other topical and systemic therapies in the treatment of chronic pruritic dermatitis, pharmacological therapy of chronic pruritus remains unestablished and is challenging [1]. Thus, new antipruritic agents need to be developed.

It has been reported that phosphodiesterase (PDE) 4, which catalyses the conversion of cyclic adenosine 3′,5′-monophosphate (cAMP) to 5′-AMP, plays a critical role in the pathogenesis of inflammatory disorders, and PDE4 inhibitors exert anti-inflammatory effects against these diseases [2–6]. Repeated topical application of a PDE4 inhibitor has been shown to improve the clinical dermatitis score in the lesional skin of patients with atopic

Abbreviations: cAMP, cyclic adenosine 3′,5′-monophosphate; EIA, enzyme immunoassay; IgG, immunoglobulin G; LTB_4, leukotriene B4; PDE, phosphodiesterase; PAR_2, proteinase-activated receptor 2; PBS, phosphate-buffered saline.

* Corresponding author at: Department of Applied Pharmacology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama 930-1094, Japan. Tel.: +81 76 434 7510; fax: +81 76 434 5045.
E-mail address: kuraisiy@pha.u-toyama.ac.jp (Y. Kuraishi).

http://dx.doi.org/10.1016/j.jdermsci.2014.10.005
0923-1811/

dermatitis [7]. Recently, a potent and selective PDE4 inhibitor, E6005, has been developed and shown to be effective after topical cutaneous dosing [8]. In patients with atopic dermatitis, twice-daily topical application of 0.2% E6005 ointment relieves atopic eczema and reduces pruritus after 12-week dosing [9]. In animal experiments, repeated topical application of 0.03% E6005 inhibits hapten-induced dermatitis in mice [8]. Interestingly, single topical application of E6005 (0.03% and lower) inhibits hapten-induced scratching in sensitized mice [8] and spontaneous scratching in mice with chronic dermatitis [10]. These findings raised the possibility that E6005 has an acute antipruritic activity, although its anti-inflammatory effect after repeated application may also contribute to the relief of pruritus. In this study, we investigated the underlying mechanisms of acute antipuritic action of E6005.

Spontaneous scratching in NC mice with chronic dermatitis is at least partly mediated by serine protease(s) and proteinase-activated receptor-2 (PAR_2) [11]. PAR_2 is also claimed to be involved in itching in patients with atopic dermatitis [12]. Therefore, we asked whether E6005-induced increase in intracellular cAMP might inhibit PAR_2-mediated itching. Leukotriene B_4 (LTB_4) is involved in PAR_2-associated scratching [13] and in spontaneous scratching in NC mice with chronic dermatitis [14]. Therefore, we also asked whether E6005-induced increase in cAMP might affect PAR_2-mediated LTB_4 production in the skin.

2. Materials and methods

2.1. Animals

Male ICR mice (Japan SLC, Hamamatsu) were used at 4–7 weeks of age except for a series of experiments, in which neonates were used to prepare primary cultures of epidermal keratinocytes. The mice were housed in a room under controlled temperature (22 ± 1 °C), humidity (55 ± 10%), and light (lights on from 07:00 to 19:00 h). Food and water were freely available. The day before the experiments, hair was removed from the rostral part of the back for intradermal injection and topical application. Procedures in the animal experiments were approved by the Committee for Animal Experiments at the University of Toyama and were conducted in accordance with the guidelines for proper conduct of animal experiments.

2.2. Materials

In in vivo experiments, SLIGRL-NH_2 (Sigma-Aldrich, St. Louis, MO, USA) and 8-bromoadenosine 3′,5′-cyclic monophosphate (8-Br-cAMP) (Sigma-Aldrich) were dissolved in physiological saline and injected intradermally into the rostral back in a volume of 50 μL. 8-Br-cAMP was injected intradermally 10 min before SLIGRL-NH_2 injection. E6005, methyl 4-[({3-[6,7-dimethoxy-2-(methylamino)quinazolin-4-yl]phenyl}amino)carbonyl]benzoate [8] (a gift from Eisai Co., Ltd., Tokyo) was dissolved in acetone–ethanol (1:1) mixture and applied to the rostral part of the back (the application area was about 4 × 4 cm) 1 h before SLIGRL-NH_2 injection. Zileuton (Sigma-Aldrich) was dissolved in 0.5% carboxymethyl cellulose (Wako Pure Chemical Ind., Osaka) and administered orally 1 h before SLIGRL-NH_2 injection.

In in vitro experiments, SLIGRL-NH_2, E6005, and 8-Br-cAMP were dissolved in culture medium containing 0.1% dimethyl sulfoxide, which was added to increase the solubility of E6005. These three agents were administered by replacing the culture medium with the agent-containing culture medium. E6005 and 8-Br-cAMP were administered 1 h and 10 min before SLIGRUL-NH_2 administration, respectively.

2.3. Behavioral experiments

The animals were put individually in an acrylic cage composed of four cells (13 × 9 × 35 cm) for at least 1 h for acclimation. Immediately after SLIGRL-NH_2 injection, the animals were returned to the same cells, and their behaviors were videotaped for 1 h with personnel kept out of the observation room. Playback of the video served for determination of hind-paw scratching of the rostral back as an index of itching [15]. When mice scratch, they stretch their hind paw toward the treated site, lean the head toward the hind paw, rapidly move the paw several times, and then lower it back to the floor; a series of these movements was counted as one bout of scratching [16].

2.4. Electrophysiological recording

The animals were deeply anaesthetized with sodium pentobarbital (80 mg/kg, intraperitoneal, Sigma-Aldrich) 40 min after application of E6005. The animal was laid in the prone position and the skin of the rostral back was turned inside out. The cutaneous nerve branch was then exposed, dissected free from surrounding tissues, and maintained in a mineral oil pool. Extracellular recording of nerve activity was performed using bipolar electrodes of silver wire (Unique Medical Co., Ltd., Tokyo) and an AC bioelectric amplifier (AB651; Nihon Kohden, Tokyo) with a band-pass filter (high-cut filter, 3 kHz; low-cut filter, 150 Hz). Compound action potentials were counted using a data analysis system with software to analyze the spike height histogram (PowerLab/8s; AD Instruments Pty, Castle Hill, Australia). SLIGRL-NH_2 and saline were injected intradermally into the receptive field 1 h after E6005 application.

2.5. Primary cultures of murine keratinocytes

The skin was removed from neonatal mice and treated with 0.05% collagenase A (Roche Diagnostics GmbH, Mannheim, Germany) dissolved in serum-free MCDB 153 medium (Sigma-Aldrich) containing 0.67% 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (Dojindo, Kumamoto, Japan), 0.12% sodium bicarbonate (Wako Pure Chemical Ind.), 0.01% penicillin G (Meiji Seika Pharma Co., Ltd., Tokyo, Japan), and 0.006% kanamycin (Wako Pure Chemical Ind.) at 4 °C overnight. Isolated murine keratinocytes were cultured in 200 μL of keratinocyte growth medium (CELLnTEC Advanced Cell Systems AG, Bern, Switzerland).

2.6. Measurement of cAMP

The animals were anaesthetized with pentobarbital (80 mg/kg, intraperitoneal) and transcardially perfused with phosphate-buffered saline (PBS). The skin at the E6005 application site was isolated using an 8-mm diameter punch 1 h after E6005 application or 5 min after pruritogen injection. The skin was frozen with liquid nitrogen and kept at −80 °C until use. The skin samples were homogenized in a lysis buffer supplied in a cAMP enzyme immunoassay (EIA) kit (GE Healthcare Bio-Sciences Co., Piscataway, NJ, USA) using a Polytron homogenizer (Robert Bosch Tool Corp., Mt. Prospect, IL, USA). After centrifugation at 600 × g at 4 °C for 5 min, the supernatant was analyzed for cAMP using the cAMP EIA kit. A part of the supernatant was used for protein measurement using a protein assay kit (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The concentration of cAMP was normalized to the protein amount.

2.7. Measurement of LTB_4

To measure LTB_4 content in the skin, the skin at the injection site was isolated 5 min after the injection of SLIGRL-NH_2 and stored

at −80 °C, as described above. LTB_4 content in the skin was determined as previously described [14]. The skin samples were homogenized in ethanol containing 10 μM indomethacin (Sigma-Aldrich) and 10 μM zileuton (Sigma-Aldrich) to inhibit cyclooxygenase and 5-lipoxygenase, respectively. After the homogenization and centrifugation, as described above, the supernatant was diluted 1:5 with double-distilled water, and the pH adjusted to 3.5 with 1 N HCl. The sample was then applied to a C_{18} Sep-Pak cartridge (Waters, Milford, MA, USA) equilibrated with methanol. After the cartridge was washed with hexane and then double-distilled water, lipids were eluted with ethanol. After the evaporation of the eluate, the residue was suspended in an EIA buffer (Cayman Chemical, Ann Arbor, MI, USA) for the assay of LTB_4. The LTB_4 content in the skin was determined using an EIA kit (Cayman Chemical) and normalized to tissue weight.

To measure LTB_4 production in keratinocytes, the culture medium (200 μL) was collected (removed) from primary cultures of murine keratinocytes 5 min after SLIGRL-NH_2 administration and assayed for LTB_4 with an EIA kit (Cayman Chemical). The remaining keratinocytes were treated with 1% Triton X-100 and used for protein determination with a protein assay kit (Bio-Rad Laboratories, Inc.). The amount of LTB_4 was normalized to the amount of protein.

2.8. Immunohistochemistry

Under anesthesia with pentobarbital (80 mg/kg, intraperitoneal), the animals were transcardially perfused with PBS and then 4% paraformaldehyde. The skin of the rostral back was isolated, postfixed with 4% paraformaldehyde, and immersed in 30% sucrose solution for 2 days. The tissue was embedded in Tissue-Tek® O.C.T. compound (Sakura Fineteck Co., Ltd., Tokyo) and kept at −80 °C until use. The frozen samples were sectioned at 20 μm with a cryostat (Leica, Wetzlar, Germany). After being washed three times with PBS, the sections were treated with 0.3% Triton X-100 in PBS and then with 0.25% fetal bovine serum to block non-specific immunoglobulin binding. The sections were treated with the first antibodies at a dilution of 1/500 at 4 °C overnight; the antibodies used were rabbit antibodies against PDE4A, 4B, 4C, and 4D (Santa Cruz Biotechnology Inc., Santa Cruz, CA) and goat anti-mouse mast cell protease 7 (mMCP7) antibody (R&D Systems, Inc., Minneapolis, MN, USA). After washing, the preparations were incubated with Alexa Fluor 594-conjugated anti-rabbit IgG and Alexa Fluor 488-conjugated anti-goat IgG antibodies (Life Technologies, Carlsbad, CA, USA) for 1 h at room temperature. Fluorescence signals were observed using a confocal laser-scanning microscope (Bio-Rad).

2.9. Statistical analysis

Data are presented as means ± standard error of the mean. Data were analyzed using a Student's *t*-test or one-way analysis of variance and a post hoc Holm–Šidák test; $p < 0.05$ was considered significant. The statistical analyses were performed using Sigmaplot graphing and statistical software (version 11; Systat Software, Ltd., Chicago, IL, USA).

3. Results

3.1. Effects of E6005 and 8-Br-cAMP on SLIGRL-NH_2-induced scratching

An intradermal injection of SLIGRL-NH_2 (100 nmol/site), a PAR_2 agonist peptide, elicited hind-paw scratching of the injection site; the effect peaked during the first 10-min period and almost subsided by 40 min (Fig. 1A). One-hour topical pretreatment with



Fig. 1. Inhibitory effects of E6005 and 8-bromo-cAMP on scratching induced by SLIGRL-NH_2. SLIGRL-NH_2 (100 nmol/site) was injected intradermally into the rostral back of each mouse. (A) Time course of SLIGRL-NH_2-induced scratching. (B) Effects of E6005 on SLIGRL-NH_2-induced scratching. E6005 and the vehicle (VH) were applied topically to the injection site 1 h before SLIGRL-NH_2 injection. (C) Effects of 8-bromo-cAMP on SLIGRL-NH_2-induced scratching. 8-Bromo-cAMP and VH were injected intradermally 10 min before SLIGRL-NH_2 injection. Broken lines represent the average scratching bouts in the saline-injected group. Values represent mean ± standard error of the mean ($n = 8$). *$p < 0.05$ vs. VH (one-way analysis of variance followed by the Holm–Šidák test).

E6005 (0.003–0.03%) significantly inhibited SLIGRL-NH_2-induced scratching; the inhibition was partial and similar between 0.003%, 0.01%, and 0.03% (Fig. 1B). In order to ascertain the involvement of cAMP, we examined the effect of 8-Br-cAMP, a cAMP analog and cAMP-dependent protein kinase activator. Ten-minute intradermal pretreatment with 8-Br-cAMP (0.01–10 nmol/site) significantly attenuated SLIGRL-NH_2-induced scratching; the inhibition was dose-dependent from 0.01 to 1 nmol/site and similar between 1 and10 nmol/site (Fig. 1C). We used 0.03% E6005 and 10 nmol/site 8-Br-cAMP in the subsequent experiments.

3.2. Effects of E6005 and 8-Br-cAMP on SLIGRL-NH_2-induced cutaneous nerve firing

The activity of the cutaneous nerve innervating the rostral back was rapidly and markedly increased following intradermal injection of SLIGRL-NH_2 (100 nmol/site), decreased from 5 to 10 min, and then low and relatively constant at least until 30 min

(data not shown). The nerve activity after the SLIGRL-NH_2 injection was significantly increased as compared with saline injection (Fig. 2). The SLIGRL-NH_2-induced increase of nerve activity was significantly inhibited by 1-h pretreatment with topical 0.03% E6005 and 10-min pretreatment with intradermal 8-Br-cAMP (10 nmol/site) (Fig. 2).

3.3. Effects of E6005 on cutaneous concentration of cAMP

The cutaneous concentration of cAMP was 0.25 ± 0.01 pmol/mg protein in vehicle-treated skin ($n = 8$). One hour after the topical application of 0.03% E6005, the cutaneous concentration of cAMP increased up to 0.31 ± 0.02 pmol/mg protein ($n = 8$); the increase was slight but statistically significant (Fig. 3A). An intradermal injection of SLIGRL-NH_2 (100 nmol/site) caused 33% decrease in the cutaneous concentration of cAMP 5 min after injection, and 1-h topical pretreatment of the injection site with 0.03% E6005 reversed the SLIGRL-NH_2-induced decrease of cAMP concentration; these changes were slight but statistically significant (Fig. 3B).

3.4. Effects of E6005 and 8-Br-cAMP on SLIGRL-NH_2-induced LTB_4 production

An intradermal injection of SLIGRL-NH_2 (100 nmol/site) significantly increased the cutaneous concentration of LTB_4 5 min after the injection, as compared with the saline-injected group (Fig. 4A and B). One-hour topical pretreatment of the injection site with 0.03% E6005 significantly decreased the increased concentration of



Fig. 2. Response of the cutaneous nerve branch to SLIGRL-NH_2 injection and its suppression by E6005 and 8-bromo-cAMP (Br-cAMP). SLIGRL-NH_2 (100 nmol/site) or saline was injected intradermally into the rostral back of each mouse. E6005 (0.03%) and the vehicle (VH) were applied topically to the rostral back 1 h before SLIGRL-NH_2 injection. Br-cAMP (10 nmol/site) and VH were injected intradermally to the SLIGRL-NH_2 injection site before 10 min. (A, B) Typical ongoing activity of the cutaneous nerve branch from 20 to 30 s after injection. (C, D) Average activity of the cutaneous nerve branch for 30 min from 20 s after injection. Values represent mean ± standard error of the mean. $n = 6$ for C and 3 for D. (C) $^*p < 0.05$ vs. VH + saline, $^\#p < 0.05$ vs. VH + SLIGRL-NH_2 (one-way analysis of variance followed by the Holm–Šidák test). (D) $^\#p < 0.05$ (Student's t-test).



Fig. 3. Effects of E6005 on cutaneous cAMP concentration in mice. The concentration of cAMP in the skin was determined by enzyme immunoassay. (A) E6005 (0.03%) and the vehicle (VH) were applied topically to the rostral back, and the skin was isolated 1 h later. (B) E6005 (0.03%) and the vehicle (VH) were applied topically to the rostral back, and 1 h later SLIGRL-NH_2 (100 nmol/site) or saline was injected intradermally. The skin was isolated 5 min after SLIGRL-NH_2 or saline injection. Values represent mean ± standard error of the mean ($n = 8$). (A) $^*p < 0.05$ (Student's t-test). (B) $^*p < 0.05$ vs. VH + saline, $^\#p < 0.05$ vs. VH + SLIGRL-NH_2 (one-way analysis of variance followed by the Holm–Šidák test).

LTB_4 almost down to the level in saline-injected skin (Fig. 4A). The E6005 action was mimicked by 8-Br-cAMP, which almost completely inhibited SLIGRL-NH_2 (100 nmol/site)-induced production of LTB_4 at intradermal dose of 10 nmol/site (Fig. 4B). To confirm the involvement of 5-lipoxigenase in SLIGRL-NH_2-induced itching and LTB_4 production, we examined the effect of the 5-lipoxigenase inhibitor zileuton. One-hour pretreatment with zileuton significantly (Student's t-test) suppressed SLIGRL-NH_2 (100 nmol/site)-induced scratching at an oral dose of 100 mg/kg; the number of scratching bouts following SLIGRL-NH_2 injection was 88.9 ± 9.2 and 40.5 ± 8.1 per hour (mean ± SEM, $n = 8$ each) in control and zileuton groups, respectively. The same dose of zileuton significantly (Student's t-test) inhibited SLIGRL-NH_2-induced LTB_4 production; the content of LTB_4 was 13.1 ± 1.2 and 6.1 ± 0.6 pg/mg tissue (mean ± SEM, $n = 6$ each) in control and zileuton groups, respectively.

Five-minute treatment with SLIGRL-NH_2 (100 μM) significantly increased LTB_4 production in primary cultures of murine keratinocytes (Fig. 5). One-hour pretreatment with E6005 (3 and 30 μM) inhibited SLIGRL-NH_2-induced LTB_4 production in a concentration-dependent manner, with a statistically significant inhibition observed at 30 μM (Fig. 5). Similarly, 10-min pretreatment with 8-Br-cAMP (10 and 100 μM) inhibited SLIGRL-NH_2-induced LTB_4 production in a concentration-dependent manner, with a statistically significant inhibition observed at 100 μM (Fig. 5).

3.5. Distribution of PDE4 subtypes and mMCP7 in the skin

There are four subtypes (PDE4A, 4B, 4C, and 4D) in the PDE4 isozyme family [29,33]. Fig. 6 shows a typical distribution of PDE4



Fig. 4. Leukotriene B_4 production induced by SLIGRL-NH_2 in the mouse skin and its inhibition by topical E6005 and 8-bromo-cAMP (Br-cAMP). SLIGRL-NH_2 (100 nmol/site) or saline was injected intradermally into the rostral back, and the skin was removed after 5 min. The concentration of leukotriene B_4 was measured using an enzyme immunoassay kit (see Section 2). (A) E6005 (0.03%) and the vehicle (VH) were applied topically to the injection site 1 h before SLIGRL-NH_2 injection. (B) Br-cAMP (10 nmol/site) and VH were injected intradermally to the SLIGRL-NH_2 injection site before 10 min. Values represent mean ± standard error of the mean ($n = 6$). $^*p < 0.05$ vs. VH + saline, $^\#p < 0.05$ vs. VH + SLIGRL-NH_2 (one-way ANOVA followed by the Holm–Šidák test).



Fig. 5. Leukotriene B_4 production induced by SLIGRL-NH_2 in primary cultures of murine keratinocytes and its inhibition by E6005 and 8-bromo-cAMP (Br-cAMP). SLIGRL-NH_2 (100 μM) was administered to the cultured keratinocytes and the culture medium was collected after 5 min. Leukotriene B_4 was determined using an enzyme immunoassay kit (see Section 2). E6005 (3 and 30 μM) and Br-cAMP (10 and 100 μM) were administered 1 h and 10 min before SLIGRL-NH_2 administration, respectively. The amount of LTB_4 in the culture medium was normalized to the amount of protein in the cultured keratinocytes. Values represent mean ± standard error of the mean ($n = 6$). $^*p < 0.05$ vs. untreated control, $^\#p < 0.05$ vs. SLIGRL-NH_2-treated control (one-way ANOVA followed by the Holm–Šidák test).

subtypes in mouse skin. mMCP7 was double-immunostained as a marker of mast cells, although it was also immunostained in the epidermal keratinocytes. PDE4A, 4C, and 4D were mainly expressed in the keratinocytes and mast cells; PDE4C was expressed especially in the basal layer of epidermis (Fig. 6). PDE4B was mainly expressed in mast cells (Fig. 6).

4. Discussion

A topical application of the PDE4 inhibitor E6005 suppressed PAR_2 agonist-induced scratching and activity of the cutaneous nerve branch, suggesting that E6005 exerts antipruritic effects through a peripheral action. An intradermal pretreatment with 8-Br-cAMP also inhibited PAR_2 agonist-induced scratching and cutaneous nerve activity. Collectively, these results suggest that the increase of cAMP in the skin attenuates PAR_2-associated itching. A topical application of E6005 increased the cutaneous concentration of cAMP and inhibited the PAR_2 agonist-induced decrease of cutaneous cAMP. These results support the above-mentioned theory. Although PAR_2, a G protein-coupled receptor, was reported not to form stable complexes with $G\alpha_o$, $G\alpha_{i1}$, and $G\alpha_{i2}$ [17], SLIGRL-NH_2 has been shown to stimulate $G\alpha_{i1}$ and inhibit forskolin-stimulated cAMP formation [18]. Further studies are needed to elucidate the mechanisms of the PAR_2-mediated decrease in the cutaneous cAMP concentration.

PDE4A, 4C, and 4D subtypes were densely located in the epidermal keratinocytes. PAR_2 receptors are also densely located in the epidermal keratinocytes [11,12]. Therefore, keratinocytes are a probable site for the suppressive action of E6005 on SLIGRL-NH_2-induced scratching. In cultured mouse keratinocytes, SLIGRL-NH_2 has been shown to increase the production of LTB_4, which is inhibited by the 5-lipoxygenase inhibitor zileuton [13]. Consistent with these findings, in mouse skin, SLIGRL-NH_2 increased the production of LTB_4, which was inhibited by zileuton (the present study). LTB_4 is an endogenous potent pruritogen [19], and zileuton suppresses SLIGRL-NH_2-induced scratching [13, the present study], suggesting that LTB_4 produced in epidermal keratinocytes is involved in SLIGRL-NH_2-induced scratching. The results that E6005 inhibited SLIGRL-NH_2-induced LTB_4 production in cultured murine keratinocytes raise the possibility that the inhibition of LTB_4 production in the epidermal keratinocytes is a mechanism of antipruritic action of E6005. To test this possibility, we examined the effects of topical application of E6005 on scratching induced by intradermal injections of nociceptin and substance P in mice, because LTB_4 production in the epidermal keratinocytes is involved in scratch-inducing activity of these peptides [16,20]. Topical application of E6005 significantly inhibited scratching induced by nociceptin and substance P (Supplementary Fig. S1), supporting the idea that suppression of LTB_4 production in keratinocytes is responsible for the antipruritic activity of E6005.

Supplementary Fig. S1 related to this article can be found, in the online version, at http://dx.doi.org/10.1016/j.jdermsci.2014.10.005.

SLIGRL-NH_2-induced LTB_4 production was suppressed by 8-Br-cAMP as well as E6005 in the skin and cultured keratinocytes, suggesting the involvement of an increase in intracellular cAMP in the inhibition of LTB_4 production. It has been reported that cAMP-dependent protein kinase inactivates 5-lipoxygenase through the phosphorylation of its Ser^{523} residue [21,22]. It has also been reported that the phosphorylation of Ser and Thr residues of PAR_2 results in its desensitization [23]. These activities may be involved in the inhibition of PAR_2-mediated LTB_4 production (Fig. 7). The results that topical application of E6005 reversed the SLIGRL-NH_2-induced decrease of cutaneous cAMP concentration supports the above-mentioned idea.

All four PDE4 subtypes were present in mast cells in the dermis (the present study). In humans, approximately half of cutaneous mast cells have PAR_2 receptors on the cell membrane and SLIGRL-NH_2



Fig. 6. Typical examples of the distribution of PDE4 subtypes and mouse mast cell protease-7 (mMCP7) in mouse skin. PDE4 subtypes (red) and mMCP7 (green) were immunostained in the rostral back skin. Arrowheads indicate PDE-positive mast cells and dotted lines boundary between the dermis and epidermis. Scale bar = 100 μm.

administration to cultured human mast cells releases histamine, the amount of which is approximately half the amount of IgE-associated histamine release [24]. Therefore, PAR_2 stimulation in the human skin releases histamine from mast cells although at low levels. PDE4 inhibitors have been shown to prevent antigen-induced histamine release from mast cells through the increase of intracellular cAMP [25]. Thus, mast cells are a conceivable site for the suppressive action of E6005 on IgE- and PAR_2-associated pruritus in humans, although higher concentrations of topical E6005 may be needed to act on mast cells than to act on epidermal keratinocytes. In contrast to humans, the PAR_2 receptor is not present in mast cells in the murine skin [11] and SLIGRL-NH_2-induced scratching is not inhibited by an H_1 histamine receptor antagonist in mice [26]. Thus, mast cells may not be a predominant site for the antipruritic action of topically applied E6005 in mice.

Although at low levels, mRNAs for all PDE4 subtypes are expressed in human dorsal root ganglia [27], raising the possibility that PDE4 subtypes are present in the primary afferents. PAR_2 has been reported to be present in neurons in the rat dorsal root ganglion [28] and in nerve fiber-like structures in human skin [12]. Thus, the primary afferents are also a conceivable site for the suppressive action of E6005 on SLIGRL-NH_2-induced scratching. However, we could not locate PDE4 subtype-positive nerve fibers in murine skin. In addition, PAR_2-positive nerve fibers were not



Fig. 7. Possible mechanism of the antipruritic effect of E6005. Stimulation of proteinase-activated receptor 2 (PAR_2) produces leukotriene B_4 (LTB_4), a pruritogen, in the epidermal keratinocytes. E6005 increases cyclic adenosine monophosphate (cAMP) by inhibition of phosphodiesterase 4 (PDE4). Increased cAMP activates protein kinase A (PKA), which phosphorylates 5-lipoxygenase (5-LOX). Phosphorylation of 5-LOX decreases the activity to inhibit LTB_4 production. 5′-AMP, 5′adenosine monophosphate; AA, arachidonic acid; LTA_4, leukotriene A_4; PLA_2, phospholipase A_2.

observed in murine skin [11]. Thus, the primary afferents may not be a site of the antipruritic action of E6005, at least in mice.

The details of the roles of the PDE4 subtypes are not completely understood. Many studies have focused on the role of PDE4 in inflammation [29]. Studies using gene knockout mice have suggested that an inhibitor of PDE4B, but not the other subtypes, shows anti-inflammatory effects [30–32]. In the present study, although all PDE4 subtypes were observed in the skin, PED4A, 4C, and 4D were present in the epidermal keratinocytes. These PDE4 subtypes may be important target molecule for the antipruritic action of topically applied E6005. However, we used naïve mice in this study. PDE4 is also expressed in immune cells (e.g., T cells, eosinophils, neutrophils, dendritic cells, monocytes, and macrophages) and its regulation is important for the treatment of inflammation [29,33]. These immune cells are also present in the skin of pruritic skin disease (e.g., atopic dermatitis) [34]. Thus, our results do not exclude the possibility that these immune cells are the site(s) of action of E6005 in dermatitis conditions.

In summary, topical application of the PDE4 inhibitor E6005 inhibited PAR_2-mediated scratching, which might be mediated by the inhibition of PAR_2-mediated LTB_4 production in the skin through the increase of the cutaneous concentration of cAMP (Fig. 7). Epidermal keratinocytes are suggested to be an important site for the antipruritic action of topical E6005. Topical PDE4 inhibitors, including E6005, may be useful for the treatment of PAR_2- and LTB_4-associated pruritic skin diseases.

Acknowledgement

This study was supported in part by Eisai Co. Ltd. (Tokyo, Japan) and Grants for Health Science from the Health, Labour and Welfare Ministry, Japan [H24-007, H26-007].

References

[1] Ständer S, Weisshaar E, Luger TA. Neurophysiological and neurochemical basis of modern pruritus treatment. Exp Dermatol 2008;17:161–9.
[2] Doherty AM. Phosphodiesterase 4 inhibitors as novel anti-inflammatory agents. Curr Opin Chem Biol 1999;3:466–73.
[3] Hoppmann J, Bäumer W, Galetzka C, Höfgen N, Kietzmann M, Rundfeldt C. The phosphodiesterase 4 inhibitor AWD 12-281 is active in a new guinea-pig model of allergic skin inflammation predictive of human skin penetration and suppresses both Th1 and Th2 cytokines in mice. J Pharm Pharmacol 2005;57:1609–17.
[4] Bäumer W, Hoppmann J, Rundfeldt C, Kietzmann M. Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets 2007;6:17–26.
[5] Harada D, Takada C, Nosaka Y, Takashima Y, Kobayashi K, Takaba K, et al. Effect of orally administered KF66490, a phosphodiesterase 4 inhibitor, on dermatitis in mouse models. Int Immunopharmacol 2009;9:55–62.
[6] Akama T, Baker SJ, Zhang YK, Hernandez V, Zhou H, Sanders V, et al. Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis. Bioorg Med Chem Lett 2009;19:2129–32.
[7] Hanifin JM, Chan SC, Cheng JB, Tofte SJ, Henderson Jr WR, Kirby DS, et al. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Invest Dermatol 1996;107:51–6.
[8] Ishii N, Shirato M, Wakita H, Miyazaki K, Takase Y, Asano O, et al. Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model. J Pharmacol Exp Ther 2013;346:105–12.
[9] Furue M, Kitahara Y, Akama H, Hojo S, Hayashi N, Nakagawa H. Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: Results of a randomized, vehicle-controlled, multicenter clinical trial. J Dermatol 2014;41:577–85.
[10] Andoh T, Yoshida T, Kuraishi Y. Topical E6005, a novel phosphodiesterase 4 inhibitor, attenuates spontaneous itch-related responses in mice with chronic atopy-like dermatitis. Exp Dermatol 2014;23:359–61.
[11] Tsujii K, Andoh T, Ui H, Lee JB, Kuraishi Y. Involvement of tryptase and proteinase-activated receptor-2 in spontaneous itch-associated response in mice with atopy-like dermatitis. J Pharmacol Sci 2009;109:388–95.
[12] Steinhoff M, Neisius U, Ikoma A, Fartasch M, Heyer G, Skov PS, et al. Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. J Neurosci 2003;23:6176–80.
[13] Zhu Y, Wang XR, Peng C, Xu JG, Liu YX, Wu L, et al. Induction of leukotriene B_4 and prostaglandin E_2 release from keratinocytes by protease-activated receptor-2-activating peptide in ICR mice. Int Immunopharmacol 2009;9:1332–6.
[14] Andoh T, Haza S, Saito A, Kuraishi Y. Involvement of leukotriene B_4 in spontaneous itch-related behaviour in NC mice with atopic dermatitis-like skin lesions. Exp Dermatol 2011;20:S94–8.
[15] Kuraishi Y, Nagasawa T, Hayashi K, Satoh M. Scratching behavior induced by pruritogenic but not algesiogenic agents in mice. Eur J Pharmacol 1995;275:229–33.
[16] Andoh T, Yageta Y, Takeshima H, Kuraishi Y. Intradermal nociceptin elicits itch-associated responses through leukotriene B_4 in mice. J Invest Dermatol 2004;123:196–201.
[17] McCoy KL, Traynelis SF, Hepler JR. PAR1 and PAR2 couple to overlapping and distinct sets of G proteins and linked signaling pathways to differentially regulate cell physiology. Mol Pharmacol 2010;77:1005–15.
[18] Sriwai W, Mahavadi S, Al-Shboul O, Grider JR, Murthy KS. Distinctive G protein-dependent signaling by protease-activated receptor 2 (PAR2) in smooth muscle: Feedback inhibition of RhoA by cAMP-independent PKA. PLoS ONE 2013;8:e66743.
[19] Andoh T, Kuraishi Y. Intradermal leukotriene B_4, but not prostaglandin E_2, induces itch-associated responses in mice. Eur J Pharmacol 1998;353:93–6.
[20] Andoh T, Katsube N, Maruyama M, Kuraishi Y. Involvement of leukotriene B_4 in substance P-induced itch-associated response in mice. J Invest Dermatol 2001;117:1621–6.
[21] Luo M, Jones SM, Phare SM, Coffey MJ, Peters-Golden M, Brock TG. Protein kinase A inhibits leukotriene synthesis by phosphorylation of 5-lipoxygenase on serine 523. J Biol Chem 2004;279:41512–20.
[22] Ye Y, Lin Y, Perez-Polo JR, Uretsky BF, Ye Z, Tieu BC, et al. Phosphorylation of 5-lipoxygenase at ser523 by protein kinase A determines whether pioglitazone and atorvastatin induce proinflammatory leukotriene B_4 or anti-inflammatory 15-epi-lipoxin a4 production. J Immunol 2008;181:3515–23.
[23] Ricks TK, Trejo J. Phosphorylation of protease-activated receptor-2 differentially regulates desensitization and internalization. J Biol Chem 2009;284:34444–57.
[24] Moormann C, Artuc M, Pohl E, Varga G, Buddenkotte J, Vergnolle N, et al. Functional characterization and expression analysis of the proteinase-activated receptor-2 in human cutaneous mast cells. J Invest Dermatol 2006;126:746–55.
[25] Barreto EO, Carvalho VF, Lagente V, Lugnier C, Cordeiro RS, Martins MA, et al. Increased levels of cyclic adenosine monophosphate contribute to the hyporesponsiveness of mast cells in alloxan diabetes. Int Immunopharmacol 2004;4:755–62.
[26] Tsujii K, Andoh T, Lee JB, Kuraishi Y. Activation of proteinase-activated receptors induces itch-associated response through histamine-dependent and -independent pathways in mice. J Pharmacol Sci 2008;108:385–8.
[27] Lakics V, Karran EH, Boess FG. Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharmacology 2010;59:367–74.
[28] Steinhoff M, Vergnolle N, Young SH, Tognetto M, Amadesi S, Ennes HS, et al. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat Med 2000;6:151–8.

[29] Jin SL, Ding SL, Lin SC. Phosphodiesterase 4 and its inhibitors in inflammatory diseases. Chang Gung Med J 2012;35:197–210.
[30] Jin SL, Conti M. Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. Proc Natl Acad Sci USA 2002;99:7628–33.
[31] Jin SL, Lan L, Zoudilova M, Conti M. Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages. J Immunol 2005;175:1523–31.
[32] Jin SL, Goya S, Nakae S, Wang D, Bruss M, Hou C, et al. Phosphodiesterase 4B is essential for T_H2-cell function and development of airway hyperresponsiveness in allergic asthma. J Allergy Clin Immunol 2010;126:1252–9.
[33] Torphy TJ. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 1998;157:351–70.
[34] Cookson W. The immunogenetics of asthma and eczema: a new focus on the epithelium. Nat Rev Immunol 2004;4:978–88.